| Income Statement | 2026-04-30 | 2025-10-31 | 2025-07-31 | |
|---|---|---|---|---|
| Research, development, and clinical trial expenses, net | 5,966,673 | 6,683,643 | 5,317,669.5* | |
| General and administrative expenses | 1,654,121 | 1,639,300 | 1,483,531.25* | |
| Total operating expenses | 7,620,794 | 8,322,943 | 6,801,200.75 | |
| Operating loss | -7,620,794 | -8,322,943 | -6,801,200.75* | |
| Financial (income) expenses, net | 186,970 | 158,646 | 28,627.75* | |
| Change in fair value of the warrant liability | -123,242 | 69,201 | -189,591* | |
| Unrealized gain on investment | 137,830 | NaN | NaN | |
| Share of loss on equity investment | -64,303 | -44,830 | -56,053* | |
| Net loss for the period | -7,237,055 | -8,278,328 | -6,639,035* | |
| Net loss attributable to non-controlling interest | -72,548 | -80,763 | -61,068.25* | |
| Net loss and comprehensive loss for the period attributable to briacell | -7,164,507 | -8,197,565 | -6,577,966.75 | |
| Basic EPS | -0.99 | -4.35 | -15.547 | |
| Diluted EPS | -0.99 | -4.35 | -15.547 | |
| Basic Average Shares | 7,250,487 | 1,883,906 | 423,114 | |
| Diluted Average Shares | 7,250,487 | 1,883,906 | 423,114 | |
BriaCell Therapeutics Corp. (BCTXZ)
BriaCell Therapeutics Corp. (BCTXZ)